Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Research ushers in a new era of hope for patients with primary immune thrombocytopenia

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

Early RSV infection turns maternal allergy into a powerful driver of childhood asthma

Early RSV infection turns maternal allergy into a powerful driver of childhood asthma

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer

Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer

Extending the reach of Amperia™: Simplifying his-tagged protein quantification across expression and development workflows

Extending the reach of Amperia™: Simplifying his-tagged protein quantification across expression and development workflows

Study elucidates how anti-amyloid antibody therapy lecanemab works in Alzheimer's disease

Study elucidates how anti-amyloid antibody therapy lecanemab works in Alzheimer's disease

New antibody strategy shows promise for halting cyst growth in polycystic kidney disease

New antibody strategy shows promise for halting cyst growth in polycystic kidney disease

Preparing for the respiratory virus season: A guide for families

Preparing for the respiratory virus season: A guide for families

AI and protein language models can accelerate the design of antiviral antibodies

AI and protein language models can accelerate the design of antiviral antibodies

Rituximab shows remarkable success in adults with relapsing nephrotic syndrome

Rituximab shows remarkable success in adults with relapsing nephrotic syndrome

Northwestern team develops antibody to expose hidden pancreatic cancer cells

Northwestern team develops antibody to expose hidden pancreatic cancer cells

COVID-19, RSV, and flu vaccines remain safe and effective

COVID-19, RSV, and flu vaccines remain safe and effective

Rozanolixizumab prevents congenital heart block in high-risk pregnancy

Rozanolixizumab prevents congenital heart block in high-risk pregnancy

Logical Biological and Bcell Design announce strategic partnership for engineered disease state materials

Logical Biological and Bcell Design announce strategic partnership for engineered disease state materials

FDA grants approval to begin Phase I clinical trials of heart tissue regeneration drug AD-NP1

FDA grants approval to begin Phase I clinical trials of heart tissue regeneration drug AD-NP1

Yale researchers develop new test for early leptospirosis detection

Yale researchers develop new test for early leptospirosis detection

Nirsevimab sharply cuts RSV hospitalizations in U.S. infants during the 2024–2025 season

Nirsevimab sharply cuts RSV hospitalizations in U.S. infants during the 2024–2025 season

Researchers develop tool to predict how patients will respond to common multiple sclerosis drug

Researchers develop tool to predict how patients will respond to common multiple sclerosis drug

Scientists outline how future therapies could change type 1 diabetes care

Scientists outline how future therapies could change type 1 diabetes care

NIH awards $3.4 million to support research on Crimean-Congo hemorrhagic fever virus

NIH awards $3.4 million to support research on Crimean-Congo hemorrhagic fever virus

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.